G

Grifols SA

D
GRFS
USD
-0.04
(-0.4391%)
Market Closed
20,253.00
Volume
0.51
EPS
-
Div Yield
35.771
P/E
6,164,236,834.93
Market Cap
Today
-0.4391%
1 Week
0.166%
1 Month
5.465%
6 Months
24.332%
12 Months
1.910%
Year To Date
-21.540%
All Time
-43.206%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

EV Maker Fisker Files for Bankruptcy

18.06.2024
Stocks news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Tesla Sales Drop Amid Intensifying EV Competition

03.04.2024
Stocks news

EV Maker Fisker in Grave Trouble as Shares Tank

27.03.2024
Stocks news
More
Related Instruments
S
SGEN
(%)
USD
A
ARRY
0.135
(2.0501%)
USD
I
INCY
-0.12
(-0.1489%)
USD
AZN
AZN
0.09
(0.1381%)
USD
GSK
GSK
-0.42
(-1.1824%)
USD
REGN
REGN
-16.31
(-1.9866%)
USD
ABBV
ABBV
-0.6
(-0.3507%)
USD
MRK
MRK
-0.01
(-0.0101%)
USD

Title:
Grifols SA

Sector:
Healthcare
Industry:
Drug Manufacturers - General
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Do you need help or have a question?
Contact Us